You are here: Home » Markets » News
Business Standard

Aurobindo Pharma hits 52-week high; up 56% in six months

The stock hit a 52-week high of Rs 830, up 3%, surging 55% in past six months, as compared to 3% rise in the S&P BSE Sensex.

SI Reporter  |  Mumbai 

Shares of Aurobindo Pharma hit a 52-week high of Rs 830, up 3% on the BSE in intra-day trade in an otherwise weak market on expectations that the second half (October-March) run-rate will be better than H1 (April-September), given full benefits of gValsartan supplies will be reflected, scale-up in injectable sales and likely new niche launches. In the past six months, the stock has outperformed the market by surging 55%, as compared to 3% rise in the S&P BSE Sensex. “The company reported strong H1FY19 US sales, aided by new launches & order wins and benefits of shortage of ...

MONTHLY STAR

Business Standard Digital

Business Standard Digital Monthly Subscription
149.00  
subscribe
Complete access to the premium product
Convenient - Pay as you go
Pay using Master/Visa Credit Card & ICICI VISA Debit Card
Auto renewed (subject to your card issuer's permission)
Cancel any time in the future
Requires personal information

What you get?

ON BUSINESS STANDARD DIGITAL

  • Unlimited access to all the content on any device through browser or app.
  • Exclusive content, features, opinions and comment – hand-picked by our editors, just for you.
  • Pick 5 of your favourite companies. Get a daily email with all the news updates on them.
  • Track the industry of your choice with a daily newsletter specific to that industry.
  • Stay on top of your investments. Track stock prices in your portfolio.
  • 18 years of archival data.

NOTE :

  • The product is a monthly auto renewal product.
  • Cancellation Policy: You can cancel any time in the future without assigning any reasons, but 48 hours prior to your card being charged for renewal. We do not offer any refunds.
  • To cancel, communicate from your registered email id and send the email with the cancellation request to assist@bsmail.in. Include your contact number for speedy action. Requests mailed to any other ID will not be acknowledged or actioned upon.

SMART MONTHLY

Business Standard Digital

Business Standard Digital - 12 Months
1499.00
subscribe
Get 12 months of Business Standard digital access
Single Seamless Sign-up to Business Standard Digital
Convenient - Once a year payment
Pay using an instrument of your choice - Credit/Debit Cards, Net Banking, Payment Wallets accepted
Exclusive Invite to select Business Standard events

What you get

ON BUSINESS STANDARD DIGITAL

  • Unlimited access to all content on any device through browser or app.
  • Exclusive content, features, opinions and comment - hand-picked by our editors, just for you.
  • Pick 5 of your favourite companies. Get a daily email with all the news updates on them.
  • Track the industry of your choice with a daily newsletter specific to that industry.
  • Stay on top of your investments. Track stock prices in your portfolio.

NOTE :

  • This product is a monthly auto renewal product.
  • Cancellation Policy: You can cancel any time in the future without assigning any reasons, but 48 hours prior to your card being charged for renewal. We do not offer any refunds.
  • To cancel, communicate from your registered email id and send the mail with the request to assist@bsmail.in. Include your contact number for easy reference. Requests mailed to any other ID will not be acknowledged or actioned upon.
Aurobindo Pharma hits 52-week high; up 56% in six months

Market at close   The S&P BSE Sensex shed 107 points to settle at 36,134 while NSE's Nifty50 index dropped 14 points to end at 10,870.

First Published: Tue, December 04 2018. 15:24 IST
RECOMMENDED FOR YOU

Aurobindo Pharma hits 52-week high; up 56% in six months

The stock hit a 52-week high of Rs 830, up 3%, surging 55% in past six months, as compared to 3% rise in the S&P BSE Sensex.

Shares of Aurobindo Pharma hit a 52-week high of Rs 830, up 3% on the BSE in intra-day trade in an otherwise weak market on expectations that the second half (October-March) run-rate will be better than H1 (April-September), given full benefits of gValsartan supplies will be reflected, scale-up in injectable sales and likely new niche launches. In the past six months, the stock has outperformed the market by surging 55%, as compared to 3% rise in the S&P BSE Sensex. “The company reported strong H1FY19 US sales, aided by new launches & order wins and benefits of shortage of ...

image
Business Standard
177 22